CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

NCT06557096 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Circulating Tumor Cell
EGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Osimertinib 80 MG
DRUG: Bevacizumab

Sponsor

Second Affiliated Hospital of Nanchang University